Does Rallies show Form 4 insider transactions for ABCL?

Yes. Rallies tracks ABCL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ABCL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABCL. It does not provide personalized investment advice.

ABCL (AbCellera Biologics Inc. Common Shares) Stock Analysis - Insider Trades

AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of May 21, 2026, ABCL trades at $4.54 with a market cap of $1.27B and a P/E ratio of -9.37. ABCL moved +12.72% today. Year to date, ABCL is +33.24%; over the trailing twelve months it is +118.66%. Its 52-week range spans $1.89 to $6.52. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ABCL stock inside the company?

Recent ABCL insider activity includes Montalbano John S. bought 20.00K, Thermopylae Holdings Ltd. bought 38.00K, Booth Andrew bought 42.60K, Thermopylae Holdings Ltd. bought 177.46K, and Montalbano John S. bought 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ABCL Key Metrics

Key financial metrics for ABCL
Metric	Value
Price	$4.54
Market Cap	$1.27B
P/E Ratio	-9.37
EPS	$-0.48
Dividend Yield	0.00%
52-Week High	$6.52
52-Week Low	$1.89
Volume	115.64K
Avg Volume	0
Revenue (TTM)	$79.21M
Net Income	$-143.96M
Gross Margin	0.00%

Recent ABCL Insider Trades

Montalbano John S. bought 20.00K (~$95.40K) on May 14, 2026.
Thermopylae Holdings Ltd. bought 38.00K (~$130.72K) on Feb 27, 2026.
Booth Andrew bought 42.60K (~$145.69K) on Feb 27, 2026.
Thermopylae Holdings Ltd. bought 177.46K (~$580.28K) on Feb 26, 2026.
Montalbano John S. bought 50.00K (~$178.46K) on Nov 26, 2025.

Latest ABCL News

AbCellera Readies 80-Patient ABCL635 Phase II After $1B Platform Build — Mar 4, 2026
AbCellera CFO Buys 42,600 Shares as Q4 Revenue Beats by 565% — Feb 27, 2026
AbCellera Posts $75M 2025 Revenue and Funds $187M R&D as Phase 2 Begins — Feb 26, 2026
AbCellera’s Q4 EPS Loss Narrows 83%, Revenue Up $39.8M Sparks 9% Jump — Feb 25, 2026

ABCL Analyst Consensus

6 analysts cover ABCL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.75.

Common questions about ABCL

Who is trading ABCL stock inside the company?: Recent ABCL insider activity includes Montalbano John S. bought 20.00K, Thermopylae Holdings Ltd. bought 38.00K, Booth Andrew bought 42.60K, Thermopylae Holdings Ltd. bought 177.46K, and Montalbano John S. bought 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ABCL?: Yes. Rallies tracks ABCL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ABCL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABCL. It does not provide personalized investment advice.